Half-life: what it means and why medication levels rise and fall

Have you ever wondered why some medications need to be taken several times a day, while the GLP-1s most often used for obesity are injected just once a week? The answer comes down to a pharmacology concept called half-life.

In this article, you’ll learn what half-life is, why it explains the weekly injection and how medication levels behave in the body over the weeks. This is about understanding your treatment, not changing anything in it: any decision about how you use the medication is your doctor’s.

What half-life is

Half-life is the time it takes the body to cut the amount of a medication in the bloodstream by half. After one half-life, about half remains; after two, about a quarter; and so on.

Every medication has its own. Some are cleared in a few hours, which is why they need to be taken several times a day. Others stay in the body much longer.

The half-life of weekly GLP-1s

Semaglutide has a half-life of about one week, according to pharmacokinetic studies of the drug. A review published in 2018 on semaglutide’s pharmacokinetics explains that this long half-life is what makes once-weekly injections possible.

Tirzepatide is also injected once a week. A 2024 analysis pooling data from 19 studies describes a half-life of about five days, which keeps the medication in the body with weekly injections.

Why levels rise and fall

Right after each injection, the level of medication in the blood goes up. Over the following days, it gradually drops until the next injection, when it rises again. That’s why levels are said to “rise and fall” over the week.

But because the half-life is long, there’s still medication left from the previous injection when the next one comes. As injections repeat, the level builds up until it reaches a balance point, called steady state: the amount going in each week makes up for the amount going out.

The 2018 review on semaglutide notes that, with a half-life of about seven days, steady state is reached in four to five weeks at the same dose.

What this means in practice

Understanding half-life helps make sense of a few things about treatment:

• The effects don’t all show up on day one. The medication level builds up over weeks.
• Each titration step takes time. When the dose changes, the body needs a few weeks to reach the new balance.
• The medication stays in your body for a while after the last injection. That’s why it’s important for every health professional who cares for you to know you’re using it.

Why tell your other providers

Because the medication stays in the body for weeks, it matters even at appointments that have nothing to do with your treatment. The U.S. prescribing information for semaglutide for weight management instructs patients to let their healthcare providers know about any planned surgery or procedure, including those that require anesthesia or sedation. It’s also worth telling your dentist, other doctors and your pharmacist, since the medication can affect the absorption of medicines taken by mouth.

What if I miss an injection?

This is a common question, and the answer is in your medication’s label and with your doctor. The guidance varies from one medication to another and depends on how much time has passed. Don’t try to make up for it on your own: check the label and, if in doubt, talk with the team following your care.

Regularity helps

Because treatment depends on keeping medication levels steady over the weeks, regular injections are part of the care. Picking a fixed day of the week, setting a phone reminder and logging each injection, with date and site, helps you keep the routine and creates a useful history for your appointment.

Half-life sounds technical, but understanding the concept helps you be more patient with the pace of treatment and talk more easily with your doctor.

Sources

• Hall S, et al. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. Clinical Pharmacokinetics, 2018.
• Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: Pharmacometrics & Systems Pharmacology, 2024.
• U.S. Food and Drug Administration. Wegovy® (semaglutide): prescribing information. FDA.